Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): May 18, 2009
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission File
Number)
|
(IRS Employer Identification
No.)
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
|
(Address
of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of Operations
and Financial Condition.
On May
18, 2009, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a
press release announcing its operating results for the third quarter of 2009.
The Company also hosted a conference call on May 19, 2009, during which the
Company’s operating results for the third quarter of 2009 was discussed. A copy
of the press release is attached hereto as Exhibit 99.1.
Item
9.01 Financial Statements
and Exhibits.
|
Exhibit No.
|
Description
|
| |
|
|
99.1
|
Press
Release dated May 18,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
JIANGBO
PHARMACEUTICALS, INC. |
|
| |
|
|
|
|
|
By:
|
/s/ Wubo
Cao |
|
| |
Name:
|
Wubo
Cao |
|
| |
Title: |
Chief
Executive Officer |
|
| |
|
|
|
Dated:
May 21, 2009